These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

348 related items for PubMed ID: 7295089

  • 1. Middle molecule accumulation in uremia: an "extra uremic factor".
    Oulès R, Emond C, Claret G, Branger B, Mion H, Mion C.
    Artif Organs; 1981; 4 Suppl():177-83. PubMed ID: 7295089
    [Abstract] [Full Text] [Related]

  • 2. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 3. Clinical implications of uremic middle molecules in regular hemodialysis patients.
    Asaba H, Alvestrand A, Fürst P, Bergström J.
    Clin Nephrol; 1983 Apr; 19(4):179-87. PubMed ID: 6851254
    [Abstract] [Full Text] [Related]

  • 4. Plasma middle molecules in asymptomatic and "sick" uremic patients.
    Asaba H, Bergström J, Fürst P, Johnson C, Yahiel V.
    Artif Organs; 1981 Apr; 4 Suppl():137-42. PubMed ID: 7295080
    [Abstract] [Full Text] [Related]

  • 5. The effect of hemodialysis on endogenous middle molecules in uremic patients.
    Asaba H, Fürst P, Oulés R, Yahiel V, Zimmerman L, Bergström J.
    Clin Nephrol; 1979 May; 11(5):257-66. PubMed ID: 455822
    [Abstract] [Full Text] [Related]

  • 6. Accumulation and excretion of middle molecules.
    Asaba H.
    Clin Nephrol; 1983 Mar; 19(3):116-23. PubMed ID: 6839560
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Relation between middle molecules and parathyroid hormone in patients with chronic renal failure.
    Fröhling PT, Kokot F, Cernacek P, Vetter K, Kuska J, Spustova V, Kaschube I, Dzurik R.
    Miner Electrolyte Metab; 1982 Jan; 7(1):48-53. PubMed ID: 7169976
    [Abstract] [Full Text] [Related]

  • 9. Renal handling of middle molecules in uremic patients and in the isolated rat kidney.
    Lustenberger N, Schindhelm K, Nordmeyer C, Schurek HJ, Stolte H.
    Artif Organs; 1981 Jan; 4 Suppl():110-4. PubMed ID: 7295076
    [Abstract] [Full Text] [Related]

  • 10. [Depurative efficiency of intermediate and large molecules with different hemodialysis modalities].
    Maduell F.
    Nefrologia; 2005 Jan; 25 Suppl 2():15-8. PubMed ID: 16050396
    [Abstract] [Full Text] [Related]

  • 11. Concentration of plasma middle molecular weight substances and clinical condition of patients undergoing short-time regular dialysis treatment.
    Válek A, Dzúrik R, Spustová V, Válková D.
    Artif Organs; 1981 Jan; 4 Suppl():173-6. PubMed ID: 7295088
    [Abstract] [Full Text] [Related]

  • 12. Uremic toxins: a new focus on an old subject.
    Yavuz A, Tetta C, Ersoy FF, D'intini V, Ratanarat R, De Cal M, Bonello M, Bordoni V, Salvatori G, Andrikos E, Yakupoglu G, Levin NW, Ronco C.
    Semin Dial; 2005 Jan; 18(3):203-11. PubMed ID: 15934967
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Dialysis therapy: 'think differently'.
    Perrone B.
    Nephrol Dial Transplant; 2007 Jul; 22 Suppl 5():v1-2. PubMed ID: 17586840
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Effect of chromatographic fractions of blood ultrafiltrates of patients with chronic uremia on the fibrinolytic activity]].
    Popławski A, Myśliwiec M, Soszka J.
    Pol Tyg Lek; 2007 Jul; 45(40-41):810-3. PubMed ID: 2096374
    [Abstract] [Full Text] [Related]

  • 17. Serum paraoxonase activity in uremic predialysis and hemodialysis patients.
    Dirican M, Akca R, Sarandol E, Dilek K.
    J Nephrol; 2004 Jul; 17(6):813-8. PubMed ID: 15593056
    [Abstract] [Full Text] [Related]

  • 18. Skin bleeding time for the evaluation of uremic platelet dysfunction and effect of dialysis.
    Soyoral YU, Demir C, Begenik H, Esen R, Kucukoglu ME, Aldemir MN, Demirkiran D, Erkoc R.
    Clin Appl Thromb Hemost; 2012 Jul; 18(2):185-8. PubMed ID: 22327827
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.